Relapse and cytogenetic evolution in myeloid neoplasms.

Relapse and cytogenetic evolution in myeloid neoplasms. Panminerva Med. 2017 Dec;59(4):308-319 Authors: Ertz-Archambault N, Kelemen K Abstract Based on the current WHO Classification of Myeloid Neoplasms, cytogenetic findings play a central role in the diagnostic classification of the myeloid malignancies. Cytogenetic abnormalities detected at primary diagnosis may change over time. Karyotype changes can be characterized as cytogenetic evolution, cytogenetic regression or a combination of both. While the exact mechanism of cytogenetic evolution is not completely understood, the process of cytogenetic evolution is not random, but follows different, and often disease-specific patterns during progression and relapse of myeloid neoplasms. Important lessons were learned from the cytogenetic evolution pathways observed over the course of chronic myelogenous leukemia (CML), progressing through chronic phase into accelerated phase and blast crisis. Cytogenetic evolution pathways of CML are divided into major and minor route abnormalities. The major route changes include an extra Ph chromosome (+Ph) trisomy 8 (+8) and the occurrence of an i(17q). The six most common minor route abnormalities include -7, -17, +17, +21 and -Y and one structural change, t(3;21). Recently an increased number of CML cases with karyotype abnormalities in Ph-negative cells have been reported in patients treated with imatinib. These abnormalities include trisomy 8, abnormalities of chromo...
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research

Related Links:

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Myelodysplastic/Myeloproliferative Neoplasm;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Mye loid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Secondary Acute Myeloid Leuke...
Source: - Category: Research Source Type: clinical trials
We report the first phase 1 findings of BP1001. Methods In this single-centre, open-label, dose-escalation phase 1/1b trial, we enrolled participants (aged ≥18 years) with refractory or relapsed acute myeloid leukaemia, Philadelphia-chromosome-positive chronic myeloid leukaemia (in chronic, accelerated, or blast phase), acute lymphoblastic leukaemia, or myelodysplastic syndrome, at MD Anderson Cancer Center (Houston, TX, USA). We used a 3 + 3 dose escalation strategy, with at least three patients enrolled at each dose level. We administered BP1001 intravenously, twice weekly, for 28 days, with a starting dose of 5 m...
Source: The Lancet Haematology - Category: Hematology Source Type: research
We report a rare case of cutaneous myeloid sarcoma associated with chronic myeloid leukemia.
Source: Anais Brasileiros de Dermatologia - Category: Dermatology Source Type: research
Conclusions: Posttransplant MNs have a latency period between that seen in AML/MDS related to alkylators and that associated with topoisomerase II inhibitors. The cytogenetic profile suggests a mutagenic effect on leukemogenesis. The clinical outcome for AML/MDS is dismal, with death occurring at an early phase of treatment. PMID: 29228125 [PubMed - as supplied by publisher]
Source: American Journal of Clinical Pathology - Category: Pathology Authors: Tags: Am J Clin Pathol Source Type: research
This article is protected by copyright. All rights reserved
Source: Journal of Cellular Physiology - Category: Cytology Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelomonocytic Leukemia;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelofibrosis;   Polycythemia Vera;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Oth...
Source: - Category: Research Source Type: clinical trials
Conclusion We conclude that the use of fresh cells versus cryopreserved cells does not have an impact on outcomes, and selected patients can achieve long-term survival with DLI for treatment of relapse after transplantation, although the overall outcomes remain dismal. Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis of 63 patients, we found that there was no difference in out...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Environmental Health | General Medicine | Gleevec | Lessons | Leukemia | Myelodysplastic Syndrome | Study | Transplants